For decades, the medical approach to high cholesterol has been reactive: use diet, lifestyle, and medication to help the body clear out excess “bad” cholesterol (LDL) from the bloodstream. However, for millions of people, this “cleanup” method is fundamentally flawed due to their genetic makeup.
New research is shifting the paradigm. Instead of trying to fix a broken disposal system, scientists are investigating how to prevent cholesterol from being produced in the first place.
The Genetic Barrier: Why Traditional Treatments Fail
Most cholesterol medications, such as statins, work by boosting the activity of LDL receptors. Think of these receptors as docking stations on the liver that grab cholesterol from the blood and pull it into cells for processing.
However, many individuals suffer from Familial Hypercholesterolemia (FH), a common genetic disorder where these “docking stations” are either broken or entirely missing.
– The Scale of the Problem: Approximately 1 in 200 adults carries this genetic mutation.
– The Risk: Because the body cannot effectively clear LDL, cholesterol builds up silently in the arteries, often leading to sudden heart attacks or cardiovascular events before a diagnosis is ever made.
– The Limitation: For those with FH, statins have a “ceiling” of effectiveness. If the receptors aren’t functioning, there is nothing for the drugs to stimulate.
Targeting the “Scaffolding” of Cholesterol
To bypass the receptor problem, researchers at the Medical University of South Carolina (MUSC) turned their attention to Apolipoprotein B (ApoB).
If LDL cholesterol is the cargo, ApoB is the scaffolding that holds the transport particle together. Without ApoB, the body cannot package and release cholesterol-carrying particles from the liver into the bloodstream. By targeting ApoB, scientists aim to reduce the amount of cholesterol released at the source, making the functionality of LDL receptors irrelevant.
Breakthrough Methodology: Humanized Models
One of the biggest hurdles in drug development is that mice do not process cholesterol like humans do. A drug that works in a lab mouse often fails in human clinical trials. To solve this, the MUSC team utilized two cutting-edge technologies:
- iPSC Technology: Researchers took adult human cells (such as skin or blood) and reprogrammed them into induced pluripotent stem cells (iPSCs), which were then grown into human-like liver cells. This allowed them to test compounds on actual human biology in a petri dish.
- “Avatar” Mice: When the initial compounds failed to show results in standard mice, the team used “humanized” mice—specially engineered animals carrying human liver cells. In these models, the compounds successfully lowered lipid levels, mirroring how they would likely behave in a human patient.
What the Data Tells Us
After screening 130,000 compounds, the team identified a specific molecule, dubbed DL-1, that showed significant promise.
- Precision: RNA sequencing revealed that DL-1 had minimal impact on overall gene activity, affecting only 182 genes. This suggests the drug is highly targeted and unlikely to cause broad, systemic disruption to liver function.
- Mechanism: The data suggests that DL-1 doesn’t simply “turn off” the ApoB gene; rather, it likely interferes with how the protein is processed and released, a more nuanced way of controlling cholesterol production.
The Road Ahead
It is important to note that these compounds are not yet ready for pharmacy shelves. The research is currently in the discovery phase, and significant work remains to understand the long-term safety and the exact molecular mechanics of these drugs.
However, this study marks a vital shift in pharmacology. By moving away from animal-centric models and focusing on the production phase of cholesterol rather than the clearance phase, science is moving closer to a definitive solution for those whom traditional medicine has left behind.
This research demonstrates a highly feasible way to conduct drug discovery using human systems, potentially accelerating the timeline for treatments that work in real people, not just lab animals.
Conclusion
By targeting the production of cholesterol through ApoB rather than relying on faulty clearance receptors, scientists are developing a potential lifeline for patients with genetic hypercholesterolemia. This approach moves medicine from managing a symptom to addressing the biological root cause.
